The U.S. FDA granted marketing authorization for ProSense in October 2025 for use in low-risk early-stage breast cancer, ...
Targeting Initial ‘Stage 1′ DFS & Ore Reserves conversion by H2 CY 2026. HIGHLIGHTS. DFS underway following dual Challenger ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results